Tag: Mavacamten

MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions

Coronary/Structural Heart by 0 comments

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be […]

Continue Reading →

MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy

Coronary/Structural Heart by 0 comments

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) […]

Continue Reading →

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Coronary/Structural Heart by 0 comments

SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the […]

Continue Reading →
1 2